most common glp-1 Survey: 37.5% of People Stop GLP-1s after Just 3 Months GI Adverse Effects of Glucagon-Like

A recently published, randomized, placebo-controlled trial found a greater reduction in BMI z-score (0.22 SDs) in adolescents receiving liraglutide compared with placebo

From Lizzie's insulin resistance to Jackie's journey towards a holistic understanding of metabolic health, we uncover the challenges and triumphs of their experience.

Learn how they work and who benefits from them.

We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance

Exceedingly short half-life (12 min) of GLP-1 limits its therapeutic applicability, and the implication of its new variants is under question

Weight management app Noom has revealed a major update to its GLP-1 Companion service to accompany and optimize popular GLP-1 drug therapies, which can cause temporary and long-term side effects like critical nutritional gaps and muscle loss